Notícias e Atividades da Aclaris Therapeutics
Presença
Sede: Estados Unidos
Aclaris Therapeutics é uma empresa listada sob o símbolo ACRS (US).
Executivos
Veja o organograma con seus 19 executivos principais
Biografias mais buscadas da Aclaris Therapeutics
- Neal Walker, Chief Executive Officer and Chairman of the Board
- Andrew Schiff, Director
- Maxine Gowen, Director
Criar um alerta
para seguir os movimentos de executivos da Aclaris Therapeutics.
Farmacêutica
Aclaris Therapeutics possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).
Popular M&A news in Farmacêutica
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (publicado em 4 de junho de 2026).
- Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
- Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Aclaris Therapeutics
- Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference | Aclaris Therapeutics, Inc.
- Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update | Aclaris Therapeutics, Inc.
- Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference | Aclaris Therapeutics, Inc.
- Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication f
- Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 | Aclaris Therapeutics, Inc.
- Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference | Aclaris Therapeutics, Inc.
- Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 | Aclaris Therapeutics, Inc.
- Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting | Aclaris Therapeutics, Inc.
- Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis | Aclaris Therapeutics, Inc.
- Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference | Aclaris Therapeutics, Inc.
- View more press releases Close
Redes sociais sobre Aclaris Therapeutics
- Aclaris Therapeutics na Wikipedia, Google News e Yahoo Finance
- Aclaris Therapeutics na LinkedIn, X (Twitter) e YouTube
